RESEARCH · BPC-157 + TB-500 · KIDNEY AND URINARY TRACT
BPC-157 and Thymosin Beta-4 in Kidney and Urinary Tract Research: Injury Models, Bladder Studies and the TB-500 Identity Gap
PurixLab’s BPC-157 + TB-500 10mg vial combines two research peptides: BPC-157, a 15-amino-acid fragment first studied in gastric models, and TB-500, a synthetic peptide commonly based on a short region of thymosin beta-4 (Tβ4). Earlier articles in this series covered the blend composition, liver injury and fibrosis models, ischaemia-reperfusion and cardiac injury models and pharmacokinetics. This overview turns to the kidney and the lower urinary tract. Almost all of the kidney papers summarised here used full-length Tβ4, not the short fragment often labelled TB-500. The findings below are from published studies, reported as the authors described them. The vial is for laboratory research use only, and nothing here is guidance for human or veterinary use or a claim about any PurixLab product.
Why TB-500 is not the same as thymosin β4
Tβ4 is a 43-amino-acid, highly conserved actin-sequestering peptide encoded by TMSB4X [1,2]. The material labelled TB-500 is a different analytical problem. In 2012, Esposito and colleagues identified the N-terminal acetylated 17-23 fragment of human Tβ4, Ac-LKKTETQ, in a product sold as TB-500, and they synthesised that fragment as a reference for detection in plasma and urine [3]. Results obtained with the full-length peptide therefore cannot be read as results for the fragment, or for a research blend that contains a TB-500 component.
Endogenous Tβ4 in the glomerulus
Tβ4 is expressed in podocytes of developing and adult mouse glomeruli [4,5]. Global loss of the peptide did not, by itself, change healthy glomeruli, but it worsened immune-mediated nephrotoxic nephritis, with poorer renal function, more periglomerular inflammation and fibrosis, and a redistribution of podocytes toward the Bowman capsule [4]. In a separate knockout study, angiotensin-II raised systolic blood pressure to a similar extent in wild-type and Tβ4-deficient mice, yet the deficient animals had substantially more albuminuria, less nephrin, more renal and cardiac macrophage infiltration, and a lower left-ventricular ejection fraction [6]. A 2023 review of this literature treats endogenous Tβ4 as a modifier of glomerular injury rather than a simple delivery problem [5].
Exogenous Tβ4 in kidney injury models
Several rodent models have tested added Tβ4 rather than gene deletion. In rats with unilateral ureteral obstruction, the authors reported that Tβ4 was associated with a smaller area of pathological change, lower 24-hour proteinuria, lower TGF-β and α-smooth muscle actin, higher E-cadherin, and less apoptosis of tubular epithelial cells; they attributed the pattern to inhibition of TGF-β signalling [7].
The same obstruction model also produced a more complicated result. Zuo and colleagues reported that Ac-SDKP, the N-terminal tetrapeptide released from Tβ4, reduced fibrosis in both wild-type and plasminogen activator inhibitor-1 (PAI-1) knockout mice [8]. Tβ4 plus a prolyl oligopeptidase inhibitor increased fibrosis in wild-type mice, while Tβ4 alone reduced late fibrosis in wild-type mice; both of those Tβ4 effects were absent in PAI-1 knockout mice [8].
In KK Cg-Ay/J mice, a model of type 2 diabetes, Tβ4 was associated with lower mean fasting glucose, lower haemoglobin A1c and triglycerides, a lower urinary albumin/creatinine ratio, and less renal pathological change; the same protocol did not change glucose handling or the albumin/creatinine ratio in nondiabetic C57BL mice [9]. In a rat ischaemic acute kidney injury model, aortic occlusion was followed by reperfusion; Tβ4 given before ischaemia-reperfusion, or just before reperfusion, was associated with lower urea and creatinine, less histologic injury, and lower markers of apoptosis, matrix remodelling, oxidative stress and inflammation [10]. A 2026 lipopolysaccharide model of sepsis-associated acute kidney injury reported that circulating Tβ4 fell after the challenge, and that giving Tβ4 was associated with less renal dysfunction, inflammation and apoptosis; the authors linked the pattern to suppressed phosphorylation of JNK1/2, p38 MAPK and ERK1/2 [11].
How the kidney releases Ac-SDKP from Tβ4
Prolyl oligopeptidase can hydrolyse only peptides shorter than 30 amino acids, while Tβ4 is 43 amino acids long [2]. Kumar and colleagues showed that release of Ac-SDKP required both meprin-α and prolyl oligopeptidase in vitro; kidney homogenates released the tetrapeptide from Tβ4, and that release was blocked by the meprin-α inhibitor actinonin [2]. Meprin-α knockout mice had less basal Ac-SDKP, and their kidney homogenates failed to release it from Tβ4 [2]. A 2026 review summarises this pathway across glomerular and tubular compartments and notes that findings can run in both directions, depending on the model [1].
Circulating Tβ4, and a gene-transfer study
Not every kidney paper used the peptide as an added laboratory reagent. In an observational cohort of 191 intensive-care patients with sepsis, lower circulating Tβ4 tertiles were associated with higher odds of acute kidney injury, continuous renal replacement therapy, and death at 7 and 28 days [12]. That is an association in stored blood, not an intervention result.
A different experimental approach used an adeno-associated viral vector encoding Tβ4. After adriamycin injury, which lowered podocyte Tβ4 in single-cell RNA-sequencing of isolated glomeruli, raising circulating Tβ4 with the vector was associated with less podocyte loss and less albuminuria, and added Tβ4 was reported to improve actin organisation in injured podocytes in vitro [13]. This is gene delivery of the full-length peptide, not a lyophilized vial.
BPC-157 in kidney and bladder models
The BPC-157 literature in this organ system is smaller and comes largely from one research group. In rats given gentamicin, the authors reported that BPC-157, given intraperitoneally or in drinking water, was associated with urea and creatinine values closer to those of untreated animals, preserved diuresis, no increase in renal mass, preserved tubular epithelium, and corresponding changes in malondialdehyde, nitric oxide and superoxide dismutase in kidney tissue [14]. They also used a triple nitric-oxide-agent design with L-NAME, L-arginine, or both; the authors reported that BPC-157 still dominated those combinations [14].
In cyclophosphamide-induced hemorrhagic cystitis in rats, BPC-157 given after cyclophosphamide, intraperitoneally or in drinking water, was associated with less gross and microscopic bladder injury, a smaller rise in bladder wet weight, and a return of elevated leak-point pressure toward values seen in normal rats; the same paper also reported that L-arginine attenuated structural lesions but not the functional change, while L-NAME aggravated lesions [15].
In rats with established vesicovaginal fistulas (4 mm defects, with administration started after 2 weeks), the authors reported that BPC-157 regimens stopped urinary leaking through the vagina within 1 week, and that by later time points the defects had closed, the bladder could hold a larger volume, and stones had not formed, whereas control fistulas still leaked and formed stones by day 56 [16]. Two rat stress-urinary-incontinence models, transabdominal urethrolysis and prolonged vaginal dilatation, were used to measure leak-point pressure. The authors reported that BPC-157, given intraperitoneally or in drinking water, counteracted the fall in leak-point pressure; some groups reached values originally noted in healthy rats, while BPC-157 did not change leak-point pressure in healthy animals [17].
A small human pilot, and its limits
Human data are thin. One 2024 pilot in Alternative Therapies in Health and Medicine enrolled 12 women with interstitial cystitis who had not responded to pentosan polysulfate [18]. The authors reported administering BPC-157 around the inflamed area of the bladder during a single cystoscopy procedure; 10 of the 12 women reported complete resolution of symptoms, and the other 2 reported that most symptoms had resolved, with no dropouts and no adverse events recorded [18]. The study had no placebo control, no blinding and no comparator procedure, and it was conducted at a single private clinic. It does not establish efficacy and is not a basis for any use of a PurixLab product.
What remains open
- TB-500 is not Tβ4. The kidney and bladder papers above used full-length Tβ4 or BPC-157. The short Ac-LKKTETQ fragment identified in a TB-500 product has not been tested in these models [3].
- No combination data. None of the studies used a BPC-157 and TB-500 blend, or BPC-157 plus full-length Tβ4, in a kidney or bladder model.
- Processing can reverse the readout. Tβ4 can appear profibrotic or antifibrotic in the same obstruction model depending on whether it is processed to Ac-SDKP and on PAI-1 status [8].
- One research group dominates the BPC-157 urinary papers. Independent replication is limited [14,15,16,17].
- Human evidence is not a controlled trial. The sepsis cohort is observational [12], the gene-transfer work is a mouse vector study [13], and the interstitial cystitis pilot is uncontrolled [18].
BPC-157 + TB-500 10mg at PurixLab
BPC-157 + TB-500 10mg: a labelled lyophilized research vial with BPC-157 5mg + TB-500 5mg per vial (10mg total), C$89 per vial (CAD, before tax), supplied for laboratory research only. It is not the full-length thymosin β4, the Ac-LKKTETQ fragment, or the BPC-157 materials described in the studies above. The product page does not currently show a certificate of analysis. If your project needs particular supporting documentation, email [email protected] before ordering and tell us what you need. Product page: purixlab.com/product/bpc-157-tb-500-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout). Current offers are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Di H, Huang J, Zhang D, et al. Thymosin beta 4: An emerging therapeutic candidate for kidney diseases. Peptides. 2026;195:171467. PubMed 41570941 · doi:10.1016/j.peptides.2026.171467
- Kumar N, Nakagawa P, Janic B, et al. The anti-inflammatory peptide Ac-SDKP is released from thymosin-β4 by renal meprin-α and prolyl oligopeptidase. Am J Physiol Renal Physiol. 2016;310(10):F1026-34. PubMed 26962108 · PMC4889319 · doi:10.1152/ajprenal.00562.2015
- Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. PubMed 22962027 · doi:10.1002/dta.1402
- Vasilopoulou E, Kolatsi-Joannou M, Lindenmeyer MT, et al. Loss of endogenous thymosin β4 accelerates glomerular disease. Kidney Int. 2016;90(5):1056-1070. PubMed 27575556 · PMC5073078 · doi:10.1016/j.kint.2016.06.032
- Mason WJ, Vasilopoulou E. The Pathophysiological Role of Thymosin β4 in the Kidney Glomerulus. Int J Mol Sci. 2023;24(9):7684. PubMed 37175390 · PMC10177875 · doi:10.3390/ijms24097684
- Kumar N, Liao TD, Romero CA, et al. Thymosin β4 Deficiency Exacerbates Renal and Cardiac Injury in Angiotensin-II-Induced Hypertension. Hypertension. 2018;71(6):1133-1142. PubMed 29632102 · PMC5945311 · doi:10.1161/HYPERTENSIONAHA.118.10952
- Yuan J, Shen Y, Yang X, et al. Thymosin β4 alleviates renal fibrosis and tubular cell apoptosis through TGF-β pathway inhibition in UUO rat models. BMC Nephrol. 2017;18(1):314. PubMed 29047363 · PMC5648500 · doi:10.1186/s12882-017-0708-1
- Zuo Y, Chun B, Potthoff SA, et al. Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis. Kidney Int. 2013;84(6):1166-75. PubMed 23739235 · PMC3830708 · doi:10.1038/ki.2013.209
- Zhu J, Su LP, Zhou Y, et al. Thymosin β4 attenuates early diabetic nephropathy in a mouse model of type 2 diabetes mellitus. Am J Ther. 2015;22(2):141-6. PubMed 23846524 · doi:10.1097/MJT.0b013e3182785ecc
- Aksu U, Yaman OM, Guner I, et al. The Protective Effects of Thymosin-β-4 in a Rat Model of Ischemic Acute Kidney Injury. J Invest Surg. 2021;34(6):601-609. PubMed 31702404 · doi:10.1080/08941939.2019.1672841
- Ouyang X, Long Z, Xu X, et al. Thymosin β4 alleviates sepsis-associated acute kidney injury by suppressing MAPK signaling pathway. Clin Sci (Lond). 2026;140(8):1695-1708. PubMed 42417058 · doi:10.1042/CS20261084
- Zhang J, Long M, Sun Z, et al. Association between Thymosin beta-4, acute kidney injury, and mortality in patients with sepsis: An observational cohort study. Int Immunopharmacol. 2021;101(Pt A):108167. PubMed 34607232 · doi:10.1016/j.intimp.2021.108167
- Mason WJ, Jafree DJ, Pomeranz G, et al. Systemic gene therapy with thymosin β4 alleviates glomerular injury in mice. Sci Rep. 2022;12(1):12172. PubMed 35842494 · PMC9288454 · doi:10.1038/s41598-022-16287-z
- Vukoja I, Vlainic J, Francina M, et al. Stable pentadecapeptide therapy counteracts gentamicin-induced nephrotoxicity via nitric oxide-system modulation: evidence from a triple nitric oxide-agent approach in rats. J Physiol Pharmacol. 2026;77(3):377-395. PubMed 42533460 · doi:10.26402/jpp.2026.3.08
- Sucic M, Luetic K, Jandric I, et al. Therapy of the rat hemorrhagic cystitis induced by cyclophosphamide. Stable gastric pentadecapeptide BPC 157, L-arginine, L-NAME. Eur J Pharmacol. 2019;861:172593. PubMed 31401154 · doi:10.1016/j.ejphar.2019.172593
- Rasic D, Zenko Sever A, Rasic F, et al. Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats. Biomedicines. 2021;9(9):1206. PubMed 34572392 · PMC8465604 · doi:10.3390/biomedicines9091206
- Jandric I, Vrcic H, Jandric Balen M, et al. Salutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats. Med Sci Monit Basic Res. 2013;19:93-102. PubMed 23478678 · PMC3940704 · doi:10.12659/MSMBR.883828
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. PubMed 39325560